|
| |
| | MedlinePlus Drug Information: Imatinib (Systemic) |
 | | Before you begin treatment with imatinib, you and your doctor should talk about the good this medicine will do as well as the risks of using it. | | | While you are being treated with imatinib, and after you stop treatment with it, do not have any immunizations (vaccinations) without your doctor's approval. | | | Liver disease—Effects may be increased because of slower removal of imatinib from the body |
|
http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/500297.html
(1551 words)
|
|
| |
| | IMATINIB |
| | Imatinib is considered to offer an important advance in the treatment of CML. | | | This is of particular importance for drugs which have a narrow therapeutic window. | | | Further trials are ongoing to fully define its place in therapy. |
|
http://www.keele.ac.uk/depts/mm/MTRAC/ProductInfo/summaries/I/IMATINIBs.html
(1284 words)
|
|
| |
| | News - Imatinib Mesylate May Be Effective in Treating Advanced Gastrointestinal Stromal Tumours |
| | Good response and improvements in performance are seen after imatinib treatment in patients with advanced gastrointestinal stromal tumours, according to observations in 2 patients whose disease was not amenable to surgery, chemotherapy or radiation therapy. | | | Imatinib Mesylate May Be Effective in Treating Advanced Gastrointestinal Stromal Tumours | | | News - Imatinib Mesylate May Be Effective in Treating Advanced Gastrointestinal Stromal Tumours |
|
http://www.docguide.com/news/content.nsf/news/8525697700573E1885256E1C003B7501
(572 words)
|
|
| |
| | Imatinib Provides Better Leukemia Rx |
| | It now appears from a research study published in the New England Journal of Medicine (2003;348:994-1004) that the drug imatinib is more effective for patients with chronic myeloid leukemia (CML) than current combination therapy. | | | Researchers state that the study will continue for at least five years allowing them to have a better understanding of the long-term outcomes of imatinib therapy on CML patients. | | | Researchers also report 76 percent of the patients had a complete response on imatinib compared to only 14.5 percent on the other two drugs. |
|
http://www.indegene.com/Gyn/Home/indGyn_Ind_News_19-03-2003_1.asp
(277 words)
|
|
| |
| | ACS :: Cancer Drug Guide: imatinib mesylate |
| | Imatinib mesylate is a protein–tyrosine kinase inhibitor used in molecular targeted therapy to treat patients with chronic myeloid leukemia (CML). | | | Your doctor or nurse will give you specific instructions about this, and how to care for yourself if your blood counts are low. | | | Your doctor will tell you when to have your blood counts checked depending on your condition. |
|
http://cancer.org/docroot/cdg/content/cdg_imatinib_mesylate.asp?internal=1
(1077 words)
|
|
| |
| | Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs |
| | Primary blasts from advanced-stage CML patients refractory to imatinib therapy were studied by semi-solid media clonogenic assays. | | | Imatinib mesylate (STI571, Glivec, Gleevec) is a powerful inhibitor of the tyrosine kinase activity of Bcr-Abl, the oncoprotein responsible for chronic myeloid leukemia (CML). | | | This suggested that, as for other chemotherapeutic drugs, resistance to imatinib might be a problem in the clinic. |
|
http://www.nature.com/leu/journal/v16/n12/full/2402775a.html
(6163 words)
|
|
| |
| | Imatinib mesylate |
| | Imatinib is used to treat chronic myelogenous leukemia (CML) and some types of stomach cancer. | | | Clinical trials with imatinib for the treatment of other types of cancer are ongoing. | | | You may not be able to become pregnant or father a child after taking this medication. |
|
http://www.webmd.com/hw/cancer/tv7950.asp
(309 words)
|
|
| |
| | HighBeam Research: Library Search: Results |
| | Most patients receiving imatinib experience hematological and non-hematological... | | | of leukemia who are treated early with imatinib are more likely to achieve complete cytogenetic... | | | majority of CML and GIST patients on imatinib mesylate experience some undesirable... |
|
http://www.highbeam.com/library/search.asp?q=Imatinib&refid=healthcyclopedia
(651 words)
|
|
| |
| | imatinib (oral) - [Medication] |
| | Your doctor may want you to have blood tests and/or other types of tests performed to monitor for side effects and effectiveness of the medication. | | | Your pharmacist has additional information about imatinib written for health professionals that you may read. | | | Continue to take imatinib and talk to your doctor if you experience: |
|
http://www.peacehealth.org/kbase/multum/d04758a1.htm
(1072 words)
|
|
| |
| | Imatinib (Gleevec) has activity in AIDS-related Kaposi's sarcoma |
| | Given that PDGF-R and c-kit also play a role in the development of KS, researchers theorized that imatinib may be an effective strategy for treating the disease. | | | This study and others are showing that the drug is also active in other cancers that express some of the same proteins," said Henry B. Koon, MD, Instructor of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, and lead author of the study. | | | "Imatinib is a targeted therapy originally shown to be effective in treating chronic myelogenous leukemia and gastrointestinal stromal tumors. |
|
http://www.eurekalert.org/pub_releases/2004-11/asoc-ih112904.php
(658 words)
|
|
| |
| | Clinical Trial: Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone ... |
| | PURPOSE: This phase II trial is studying how well giving docetaxel with imatinib mesylate works in treating patients with androgen-independent prostate cancer and bone metastases that progressed while receiving docetaxel and a placebo on clinical trial MDA-ID-030008. | | | Determine the quality of life of patients treated with this crossover regimen. | | | Provide treatment with docetaxel and imatinib mesylate for patients with androgen-independent prostate cancer and bone metastases that progressed while receiving docetaxel and placebo on. |
|
http://clinicaltrials.gov/ct/show/NCT00084825?order=31
(613 words)
|
|
| |
| | Imatinib shows early promise against Ewing’s sarcoma |
| | The promise, he concludes, is that identification of another imatinib-sensitive kinase in Ewing's sarcoma cells could lead to improved therapy for this disease. | | | Both cancers are associated with the overactivation of a specific tyrosine kinase. | | | Imatinib is a tyrosine kinase inhibitor that has produced high response rates in patients with chronic myelogenous leukemia and gastrointestinal stromal tumors. |
|
http://www.eurekalert.org/pub_releases/2002-11/jotn-ise111402.php
(342 words)
|
|
| |
| | GSI News: Imatinib mesylate in gastrointestinal stromal tumours |
| | See also Therapy section this issue, p17; 800896526 | | | Imatinib mesylate - a new oral targeted therapy. | | | Imatinib mesylate has also shown antitumour activity in patients with gastrointestinal stromal tumours, almost all of which express c-kit and often CD34, say Drs Savage and Antman. |
|
http://www.gistsupport.org/news_20020305_1.asp
(290 words)
|
|
| |
| | Gleevec Indications, Dosage, Storage, Stability - Imatinib Mesylate - RxList Monographs |
| | Therapy should be initiated by a physician experienced in the treatment of patients with chronic myeloid leukemia or gastrointestinal stromal tumors. | | | Gleevec is also indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. | | | Gleevec® (imatinib mesylate) is indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronic phase. |
|
http://www.rxlist.com/cgi/generic3/gleevec_ids.htm
(951 words)
|
|
| |
| | Glivec International - Glivec, GIST, and CML Info for HCPs |
| | "Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience" | | | New Data on Long-Term Response to Imatinib and Implications of Rationale for Higher Dose Therapy in Ph+ CML | | | "The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long term outcome of treatment with imatinib mesylate" |
|
http://www.glivec.com
(226 words)
|
|
| |
| | FDA Approves Gleevec (Imatinib Mesylate) For Leukemia Treatment |
| | FDA Approves Gleevec (Imatinib Mesylate) For Leukemia Treatment | | | WASHINGTON, DC -- May 10, 2001 -- The Food and Drug Administration (FDA) announced the approval of Gleevec (imatinib mesylate, also known as STI-571), a promising new oral treatment for patients with chronic myeloid leukemia (CML) -- a rare life-threatening form of cancer. | | | FDA reviewed the marketing application for Gleevec in less than three months under its "accelerated approval" regulations. |
|
http://www.pslgroup.com/dg/1FAA6A.htm
(694 words)
|
|
| |
| | Researchers reveal potential new role for Glivec/Imatinib |
| | Dasatinib Overcomes Imatinib Resistance for Chronic Myeloid Leukemia | | | In a phase 2 study, 90% of patients resistant or intolerant to imatinib experienced a complete hematologic response.Linda Little | | | AMN107 was observed to be 10- to 50-fold more potent than imatinib against BCR-ABL expressing cell lines, including mutations that develop during treatment with imatinib, researchers report.Linda... |
|
http://www.medical-buzz.com/researchers-reveal-potential-new-role-for-glivec-imatinib,17489.html
(131 words)
|
|
| |
| | Gleevec Online, Description, Chemistry, Ingredients - Imatinib Mesylate - RxList Monographs |
| | Imatinib mesylate is designated chemically as 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate and its structural formula is | | | Gleevec® (imatinib mesylate) film-coated tablets contain imatinib mesylate equivalent to 100 mg or 400 mg of imatinib free base. | | | For information on ordering Gleevec Online, please click the "online pharmacy" link on the blue horizontal navigation bar at the top of every page. |
|
http://www.rxlist.com/cgi/generic3/gleevec.htm
(175 words)
|
|
| |
| | imatinib |
| | Kinases as drug discovery targets in hematologic malignancies. | | | Imatinib also blocks the stem cell factor SCF receptor or c-KIT loop. | | | Mohty M, Blaise D, Olive D, Gaugler B. Imatinib: the narrow line between immune tolerance and activation. |
|
http://www.humpath.com/article.php3?id_article=4289
(86 words)
|
|
| |
| | Imatinib erhält die EU-Zulassung bei GIST |
| | Die U.S. Food and Drug Administration (FDA) erteilte Imatinib am 1. | | | Die Daten zeigten, dass in dieser Studie mehr als 60 % der Patienten mit GIST eine bestätigte Teilremission unter der Therapie mit Imatinib erreichten, und es bei weiteren 20 % zu einem gewissen Grad der Tumorschrumpfung oder Stabilisierung des Tumors | | | Die Zulassung folgt einer positiven Empfehlung durch das Committee for Proprietary Medicine (CPMP) der EU im Februar 2002. |
|
http://www.krebs-kompass.de/Krebsnews/article/Magenkrebs/1022885084.html
(722 words)
|
|
| |
| | LMC et imatinib |
| | 23 % des patients sous interféron ont dû interrompre leur traitement du fait d’effets secondaires contre moins de 1 % dans le groupe imatinib. | | | LMC et imatinib par Esculape.com : site de médecine générale et de santé"> | | | 19 % des sujets sous interféron ont vu leur maladie progresser à un an contre 4 % sous imatinib ; |
|
http://www.esculape.com/generale/lmc.html
(201 words)
|
|
| |
| | ANNALS ONLINE -- Sign In Page |
| | To view this item, select one of the options below: | | | Effect of Tyrosine Kinase Inhibition Using Imatinib on Normal Lymphohematopoietic... |
|
http://www.annalsnyas.org/cgi/content/full/1044/1/168
(152 words)
|
|
|
